Skip to main content
SpringerLink
Log in

Erenumab reduces burden and lost productivity due to migraine

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Porter JK, et al. Productivity Losses Among Patients with Migraine: an Analysis of Erenumab Clinical Trial Data. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus oral presentation) abstr. ND3, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/79839?pdfid=53686.

  2. Porter JK, et al. Modeling the Reduction in the Clinical Burden of Migraine with Erenumab Treatment. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PND28, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/79846?pdfid=53877.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erenumab reduces burden and lost productivity due to migraine. PharmacoEcon Outcomes News 805, 17 (2018). https://doi.org/10.1007/s40274-018-5019-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5019-7

Search

Navigation